Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.55 |
| ▸ | BCHE | P06276 | 5/20 | 0.47 |
| ▸ | BACE1 | P56817 | 7/20 | 0.46 |
| ▸ | SLC6A11 | P48066 | 1/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.46 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.46 |
| ▸ | GAA | P10253 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3355726 | 1.00 | ALDH1A1 (0.55) | ALDH1A1BCHEBACE1SLC6A11KDM4E | |
| SCHEMBL7051379 | 0.88 | BCHE (0.48) | BCHEBACE1SLC6A11KDM4ETDP1 | |
| SCHEMBL3351369 | 0.88 | BCHE (0.48) | BCHEBACE1SLC6A11KDM4ETDP1 | |
| SCHEMBL3351374 | 0.88 | BCHE (0.48) | BCHEBACE1SLC6A11KDM4ETDP1 | |
| SCHEMBL7612831 | 0.87 | KLK5 (0.54) | ALDH1A1BCHEBACE1 | |
| SCHEMBL7612824 | 0.87 | KLK5 (0.54) | ALDH1A1BCHEBACE1 | |
| SCHEMBL7606169 | 0.85 | ALDH1A1 (0.47) | ALDH1A1BCHEBACE1SLC6A11 | |
| SCHEMBL7606164 | 0.85 | ALDH1A1 (0.47) | ALDH1A1BCHEBACE1SLC6A11 | |
| SCHEMBL6889830 | 0.85 | ALDH1A1 (0.47) | ALDH1A1BCHEBACE1SLC6A11 | |
| SCHEMBL6888172 | 0.84 | BACE1 (0.51) | BCHEBACE1SLC6A11 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7727997-B2 | N,N′-substituted-1,3-diamino-2-hydroxypropane derivatives | ELAN PHARMACEUTICALS, INC. (US) | 2010-06-01 | — | — | US | disclosed |
| US-20070213316-A1 | Compounds that are effective inhibitors of beta-secretase; inhibitors of beta-secretase-mediated cleavage of amyloid precursor proteins; effective inhibitors of A beta production, and/or are effective to reduce amyloid beta deposits or plaques; treatment of disorders such as Alzheimer's Disease | ELAN PHARMACEUTICALS, INC. | 2007-09-13 | — | — | US | disclosed |
| US-20070213407-A1 | Compounds to treat Alzheimer's disease | ELAN PHARMACEUTICALS AND PHARMACIA & UPJOHN COMPANY LLC | 2007-09-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070213407-A1 | Compounds to treat Alzheimer's disease | PSEN2, PSEN1, CHAT | ALDH1A1 524/4885BCHE 8/4885BACE1 7/4885 |
| US-20070213316-A1 | Compounds that are effective inhibitors of beta-secretase; inhibitors of beta-secretase-mediated cleavage of amyloid precursor proteins; effective inhibitors of A beta production, and/or are effective to reduce amyloid beta deposits or plaques; treatment of disorders such as Alzheimer's Disease | BACE1, BACE2, APP | ALDH1A1 2133/4885BCHE 17/4885BACE1 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.